Japan Pharma Archives | Report Store | Pharma intelligence

show blocks helper

Sort by Price
- Default Order
- Name
- Price
- Date
- Popularity

Click to order products ascending

Display 15 Products per page

Shire Company Analysis

$3,000.00

PharmaVitae explores Shire’s prescription pharmaceutical performance and outlook over 2017–27. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts
August 30, 2018
Select options
Mitsubishi Tanabe Company Analysis

$3,000.00

Updated analysis and forecasts based on Q1 2017 company-reported sales.
October 6, 2017
Select options
Japan Pharma Outlook 2027

$3,000.00

PharmaVitae explores and visualizes market dynamics in the Japan Pharma peer set out to 2027* through analysis and in-house sales forecasts for more than 320 products.
July 2, 2018
Select options
Japan Pharma Outlook

$3,000.00

Datamonitor’s Japan Pharma peer set contains the top 10 companies headquartered in Japan: Takeda Pharmaceuticals, Astellas Pharma, Daiichi Sankyo, Otsuka Pharmaceutical, Eisai, Mitsubishi Tanabe Pharma, Chugai Pharmaceutical, Dainippon Sumitomo, Shionogi & Co and Kyowa Hakko Kirin.
September 28, 2016
Select options
Astellas Company Analysis

$3,000.00

Analysis of Astellas’s prescription pharmaceutical sales encompassing global corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2015–25.
September 19, 2018
Select options
Daiichi Sankyo Company Analysis

$3,000.00

PharmaVitae explores Daiichi Sankyo’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016–26.
August 22, 2017
Select options
Dainippon Sumitomo Company Analysis

$3,000.00

Analysis of Dainippon Sumitomo’s prescription pharmaceutical sales encompassing global corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2015–25.
September 19, 2017
Select options
Eisai Company Analysis

$3,000.00

Pharmavitae Analytics explores Eisai’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016–26.
August 28, 2017
Select options
Otsuka Company Analysis

$3,000.00

PharmaVitae explores Otsuka’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016–26.
August 28, 2017
Select options
Shinogi

$3,000.00

Analysis of Shionogi’s prescription pharmaceutical sales encompassing global corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2015–25.
September 28, 2016
Select options
Takeda

$3,000.00

Analysis of Takeda’s prescription pharmaceutical sales encompassing global corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2014–24.
September 19, 2017
Select options
Shionogi Company Analysis

$3,000.00

Updated analysis and forecasts based on 2016 company-reported sales.

Pharmavitae Analytics explores Shionogi’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016–26.
August 31, 2017
Select options

Japan Pharma

Japan Pharma

Shire Company Analysis

Mitsubishi Tanabe Company Analysis

Japan Pharma Outlook 2027

Japan Pharma Outlook

Astellas Company Analysis

Daiichi Sankyo Company Analysis

Dainippon Sumitomo Company Analysis

Eisai Company Analysis

Otsuka Company Analysis

Shinogi

Takeda

Shionogi Company Analysis